DK0792292T3 - Orphan-receptor - Google Patents

Orphan-receptor

Info

Publication number
DK0792292T3
DK0792292T3 DK96931047T DK96931047T DK0792292T3 DK 0792292 T3 DK0792292 T3 DK 0792292T3 DK 96931047 T DK96931047 T DK 96931047T DK 96931047 T DK96931047 T DK 96931047T DK 0792292 T3 DK0792292 T3 DK 0792292T3
Authority
DK
Denmark
Prior art keywords
amino acid
acid sequence
receptor
relates
disorders
Prior art date
Application number
DK96931047T
Other languages
English (en)
Other versions
DK0792292T4 (da
Inventor
George G J Kuiper
Eva Enmark
Jan-Ake Gustafsson
Original Assignee
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0792292(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9518272.1A external-priority patent/GB9518272D0/en
Priority claimed from GBGB9605550.4A external-priority patent/GB9605550D0/en
Priority claimed from GBGB9607532.0A external-priority patent/GB9607532D0/en
Priority claimed from GBGB9609576.5A external-priority patent/GB9609576D0/en
Application filed by Karobio Ab filed Critical Karobio Ab
Publication of DK0792292T3 publication Critical patent/DK0792292T3/da
Application granted granted Critical
Publication of DK0792292T4 publication Critical patent/DK0792292T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK96931047T 1995-09-08 1996-09-09 Orphan-receptor DK0792292T4 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9518272.1A GB9518272D0 (en) 1995-09-08 1995-09-08 Orphan receptor
GBGB9605550.4A GB9605550D0 (en) 1996-03-15 1996-03-15 Orphan receptor
GBGB9607532.0A GB9607532D0 (en) 1996-04-11 1996-04-11 Orphan receptor
GBGB9609576.5A GB9609576D0 (en) 1996-05-08 1996-05-08 Orphan receptor
PCT/EP1996/003933 WO1997009348A2 (en) 1995-09-08 1996-09-09 Orphan receptor

Publications (2)

Publication Number Publication Date
DK0792292T3 true DK0792292T3 (da) 2000-02-07
DK0792292T4 DK0792292T4 (da) 2009-07-20

Family

ID=27451339

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96931047T DK0792292T4 (da) 1995-09-08 1996-09-09 Orphan-receptor

Country Status (12)

Country Link
US (2) US5958710A (da)
EP (2) EP0792292B2 (da)
JP (4) JP3131649B2 (da)
KR (1) KR100263137B1 (da)
AT (1) ATE183516T1 (da)
AU (1) AU715528B2 (da)
CA (1) CA2201098C (da)
DE (2) DE69603827T3 (da)
DK (1) DK0792292T4 (da)
ES (1) ES2135249T5 (da)
GR (2) GR980300029T1 (da)
WO (1) WO1997009348A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200423C (en) 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
EP0866127A3 (en) * 1997-03-17 1999-12-22 Smithkline Beecham Plc HE8AN36, a steroid hormone receptor homolog
AU735703B2 (en) * 1997-06-10 2001-07-12 Karo Bio Ab Estrogen receptor ligands
US7157568B1 (en) * 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
ES2268789T3 (es) * 1997-09-08 2007-03-16 MERCK & CO., INC. Receptor de estrogeno.
GB9814620D0 (en) * 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
DE19839115A1 (de) * 1998-08-27 2000-03-09 Ihf Inst Fuer Hormon Und Fortp Klonierung und Expression von Rinder Estrogenrezeptor-beta
EP1400810A3 (en) * 1999-04-09 2005-03-02 Karo Bio Ab Estrogen receptors and bone disease
AU4546900A (en) * 1999-04-09 2000-11-14 Karo Bio Ab Estrogen receptors and bone
AU2002247702A1 (en) * 2001-02-09 2002-08-28 Lion Bioscience Ag Novel cofactors of the estrogen receptor beta and methods of use
WO2002070697A1 (en) * 2001-03-02 2002-09-12 Lion Bioscience Ag Mammalian nuclear receptor l67 and methods of use
EP1411922A1 (en) 2001-07-31 2004-04-28 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
ATE362471T1 (de) 2001-11-19 2007-06-15 Lilly Co Eli Substituierte benzopyrane als selektive agonisten am östrogenrezeptor-beta
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
WO2003050133A1 (en) * 2001-12-07 2003-06-19 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor beta expression
CA2365811A1 (en) * 2001-12-21 2003-06-21 Institut De Cardiologie A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
RU2348653C2 (ru) 2003-02-21 2009-03-10 Дау Глобал Текнолоджиз Инк. Способ гомо- или сополимеризации сопряженных олефинов
WO2004094401A1 (en) 2003-04-21 2004-11-04 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
CN100374444C (zh) 2003-04-21 2008-03-12 伊莱利利公司 作为选择性β-雌激素受体激动剂的取代的苯并吡喃化合物
KR20060066070A (ko) 2003-07-28 2006-06-15 스미스클라인 비참 코포레이션 에스트로겐 수용체의 조절제로서의 시클로알킬리덴 화합물
EP1709443A2 (en) * 2003-12-18 2006-10-11 Procognia, Ltd. Method for analyzing a glycomolecule
KR20070061536A (ko) 2004-09-07 2007-06-13 와이어쓰 ６Ｈ-[１]벤조피라노[４,３-ｂ]퀴놀린 및 에스트로겐제제로서의 이의 용도
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5262300A (en) * 1988-11-30 1993-11-16 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5602009A (en) * 1988-12-23 1997-02-11 The Salk Institute For Biological Studies Dominant negative chimeras of the steroid/thyroid superfamily of receptors
EP0463081B1 (en) * 1989-03-17 1998-05-20 The Salk Institute For Biological Studies Hormone response element compositions and assay
US5438126A (en) * 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
WO1995013373A1 (en) * 1993-11-10 1995-05-18 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor

Also Published As

Publication number Publication date
CA2201098C (en) 2001-03-27
EP0792292A2 (en) 1997-09-03
ES2135249T3 (es) 1999-10-16
JP3131649B2 (ja) 2001-02-05
AU715528B2 (en) 2000-02-03
KR100263137B1 (ko) 2000-08-01
WO1997009348A2 (en) 1997-03-13
US20030113803A1 (en) 2003-06-19
WO1997009348A3 (en) 1997-04-24
JP2005204666A (ja) 2005-08-04
EP0792292B2 (en) 2009-04-15
US7132261B2 (en) 2006-11-07
DE69603827D1 (de) 1999-09-23
DE792292T1 (de) 1998-09-03
DE69603827T2 (de) 2000-02-24
EP0935000A2 (en) 1999-08-11
EP0792292B1 (en) 1999-08-18
GR3031618T3 (en) 2000-01-31
CA2201098A1 (en) 1997-03-13
ES2135249T5 (es) 2009-09-10
DK0792292T4 (da) 2009-07-20
JPH11502417A (ja) 1999-03-02
US5958710A (en) 1999-09-28
JP2002010788A (ja) 2002-01-15
EP0935000A3 (en) 1999-09-08
AU6988096A (en) 1997-03-27
ATE183516T1 (de) 1999-09-15
JP2005204667A (ja) 2005-08-04
GR980300029T1 (en) 1998-04-30
DE69603827T3 (de) 2009-11-05

Similar Documents

Publication Publication Date Title
DE69603827D1 (de) Waisen-rezeptor
ATE294595T1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
MX9700553A (es) Anticuerpos que activan un receptor de eritropoyetina.
ES2151277T3 (es) Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
BR9710636A (pt) Análogo de somatostatina ciclizada da espinha dorsal, uso do mesmo, composição farmacêutica,e , processo de tratamento de distúrbios endócrinos, neoplasmas ou distúrbios metabólicos.
MXPA00012586A (es) Glicosulfopeptidos y metodos de sintesis y uso de los mismos.
BR9712589A (pt) Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica.
AU6045398A (en) Androgen synthesis inhibitors
NO961706D0 (no) Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
BR9811264A (pt) Composições imunogênicas ao receptor de gastrina/cck-b e métodos para o tratamento de tumores
PL328858A1 (en) Immunogenous peptides
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
MX9708401A (es) Genes reguladores de la cromatina.
AP9801269A0 (en) Prostaglandin agonists.
LEVI-MONTALCINI et al. Hormonal control of the NGF content in the submaxillary glands of mice
Banerjee et al. Distinct colchicine binding kinetics of bovine brain tubulin lacking the type III isotype of beta-tubulin
ATE237334T1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
BR0110208A (pt) Composições e terapias para distúrbios associados com hiperlipidemia
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
BR9808784A (pt) Método para o tratamento de doença mental em mamìferos e uma composição para o mesmo
EE200000333A (et) Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod
CA2340475A1 (en) Orphan receptor